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Objective: Although leptin appears to be an important local and systemic factor inﬂuencing cartilage
homeostasis, the role of leptin in chondrocyte death is largely unknown. Tumor necrosis factor a (TNF-a)
is a pro-inﬂammatory cytokine that plays a central role in the pathogenesis of articular diseases. This
study examines whether leptin modulates TNF-a-induced articular chondrocyte death.
Methods: Primary rat articular chondrocytes were isolated from knee joint cartilage slices.
To induce cell death, the chondrocytes were treated with TNF-a. To examine whether leptin modulates
the extent of TNF-a-mediated chondrocyte death, the cells were pretreated with leptin for 3 h before
TNF-a treatment followed by viability analysis. To examine the mechanism by which leptin modulates
the extent of TNF-a-mediated chondrocyte death, we utilized mitochondrial membrane potential (MMP)
measurements, ﬂow cytometry, nuclear morphology observation, co-immunoprecipitation, western blot
analysis and confocal microscopy.
Results: We demonstrated that leptin suppresses TNF-a induced chondrocyte death. We further found
that apoptosis partially contributes to TNF-a induced chondrocyte death while necroptosis primarily
contributes to TNF-a induced chondrocyte death. In addition, we observed that leptin exerts anti-TNF-a
toxicity via c-jun N-terminal kinase (JNK) in rat articular chondrocytes.
Conclusion: Based on our ﬁndings, we suggest that the leptin present in the articular joint ﬂuid protects
articular chondrocytes against cumulative mechanical load and detrimental stresses throughout a life-
time, delaying the onset of degenerative changes in chondrocytes. We can further hypothesize that leptin
protects articular chondrocytes against destructive stimuli even in the joints of osteoarthritis (OA)
patients.
© 2015 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
Osteoarthritis (OA) is a multifactorial disease with high
morbidity that is characterized by degradation of the extracellular
matrix and destruction of articular cartilage1. Chondrocytes, theo: Y.H. Yoo, Department of
egulation Center, College of
eo-gu, Busan 602-714, South
iken@hanmail.net (J.H. Rho),
H. Kim), molecule85@pusan.
nyjjy@dau.ac.kr (N.Y. Jeong),
.H. Yoo).
ternational. Published by Elsevier Lonly resident cells in normal mature cartilage, are responsible for
remodeling and maintaining the structural and functional integrity
of the extracellular matrix. Chondrocytes show a limited prolifer-
ative activity in response to injury, making chondrocyte survival
critical for the preservation of cartilage structure and function.
Chondrocyte death and the pertinent signaling pathways
involved have therefore been the focus of interest as pathogenetic
factors leading to joint cartilage degradation in OA2. Thus, the in-
hibition of chondrocyte death has been suggested as a therapeutic
strategy to limit cartilage damage. Although the mechanisms
involved in this process are yet to be fully elucidated, stimuli which
can favor chondrocyte death in vivo include nitric oxide (NO),
prostaglandin E2, Fas ligand, tumor necrosis factor a (TNF-a) and
TNF-related apoptosis inducing ligand (TRAIL)3e8. TNF-a, a pro-td. All rights reserved.
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articular diseases such as rheumatoid arthritis (RA) and OA. Thus,
TNF-a has been targeted for therapeutic intervention9. Numerous
previous studies have demonstrated that TNF-a induces articular
chondrocytes death6,10,11.
Obesity has been traditionally thought of as a local risk factor
that contributes to OA through increased load and altered me-
chanical axis on weight-bearing joints12, but obese individuals also
have an increased risk of OA in non-weight-bearing joints such as
hands, wrists and shoulders13, suggesting that soluble factors, such
as adipokines, play a role in the onset and progression of OA. Adi-
pokines include a variety of pro-inﬂammatory factors, most of
which are increased in obesity and appear to contribute to the so-
called ‘low-grade inﬂammatory state’ in obese individuals.
Leptin is a 16 kDa hormone that was discovered in 1994 and is
produced by white adipocytes to regulate food intake and energy
expenditure14. Recently, leptin was described as a new regulator of
bone growth, acting either through a neuronal network to release
an unidentiﬁed antiosteogenic factor15,16 or directly by inducing
osteoblast proliferation, collagen synthesis, and bone mineraliza-
tion17,18. Leptin is also a skeletal growth factor that stimulates
endochondral ossiﬁcation19. Because the functional leptin receptor
has been shown to be expressed in normal human cartilage20, it can
be speculated that leptin could also act on the articular connective
tissue, especially during osteoarthritis (OA), a disease in which
great metabolic changes of chondrocytes are observed.
According to recent ﬁndings, leptin is also produced by many
other tissues and cells in addition to adipose tissue, including
various joint tissues. Leptin can be found in synovial ﬂuid in cor-
relation with the body mass index21. Moreover, leptin receptors are
expressed within the cartilage20, and leptin mediates and modu-
latesmany inﬂammatory and destructive responses in cartilage and
other joint tissues22. Therefore, leptin emerges as an attractive
candidate to link obesity and OA and serves as a putative drug
target for disease-modifying drugs for OA23.
The role of leptin in cellular death is complex and not
completely clariﬁed. Previous studies elucidated that leptin could
modulate cell death. Numerous studies have demonstrated that
leptin inhibited cell death under various conditions24e27; however,
several studies reported that leptin could enhance cell death28. A
recent study reported that leptin protects against TNF-a-induced
apoptosis in rat cardiomyocytes27. Although leptin appears to be an
important local and systemic factor inﬂuencing cartilage homeo-
stasis, the role of leptin in chondrocyte death is largely unknown.
Previously, one study reported that leptin does not induce chon-
drocyte death22. Although the presence of leptin in the synovial
ﬂuid suggests the local effect of leptin on the modulation of artic-
ular chondrocyte death, how leptin modulates articular chon-
drocyte death remains elusive.
We undertook this study to examine whether leptin modulates
articular chondrocyte death. We found that leptin protects rat
articular chondrocytes against TNF-a-induced cytotoxicity.
Methods
Materials
The following reagents were obtained commercially: Polyclonal
rabbit anti-human caspase-3, caspase-7, c-jun N-terminal kinase
(JNK) and phospho-JNK antibodies were from cell Signaling Tech-
nology (Danvers, MA); Polyclonal rabbit anti-human cytochrome c,
RIP3, cIAP1 and cIAP2 antibodies were from Santa Cruz Biotech-
nology (Santa Cruz, CA, USA); Polyclonal mouse anti-human poly-
adenosine diphosphate (ADP]-ribose (PARP) antibody was from
Oncogene (Cambridge,MA);Monoclonalmouse anti-XIAP antibodywas from Enzo Life Sciences (Farmingdale, NY); Monoclonal mouse
anti-RIP antibodywas from BD Transduction Laboratories (San Jose,
CA, USA); Fluorescein isothiocyanate-conjugated goat anti-rabbit
IgG antibody was from Vector (Burlingame, CA); TNF-a was from
Millipore (Temecula, CA); Dulbecco's Modiﬁed Eagle's Medium
(DMEM) and fetal bovine calf serum (FBS) were from Gibco (Gai-
thersburg, MD); 5,50,6,60-tetrachloro-1,10,3,30-tetraethylbenzimida-
zolyl-carbo-cyanine iodide (JC-1) from Molecular Probes (Eugene,
OR); Monoclonal mouse anti-b actin and phosphoserine antibodies,
Dimethyl sulfoxide (DMSO), Hoechst 33342, RNase A, proteinase K,
protease inhibitor cocktail, propidium iodide (PI), 30, 30-dia-
minobenzidine, emodin, type II collagenase, anisomycin (ANI),
leptin rat, cycloheximide (CHX), 5,6-dichlorobenzimidazol riboside
(DRB) and Annexin V-FITC apoptosis detection kit were from Sigma
(St. Louis, MO); necrostain-1 (Nec 1), caspase inhibitor I (zVAD-
FMK), JNK inhibitor II (SP600125), ERK inhibitor (PD98059), p38
inhibitor (SB202190) were from Merck millipore (Bedford, MA,
USA); Enhanced chemiluminescence western blotting detection
reagents SuperSignal West Pico Chemiluminescent Substrate were
from Pierce (Rockford, IL).
Cell culture of articular chondrocytes
Primary rat articular chondrocytes were isolated from knee joint
cartilage slices of 5-week old Sprague Dawley rats by enzymatic
digestion for 2 h with 0.2% collagenase type II (381 units/mg, solid;
Sigma) in DMEM. After collecting individual cells upon brief
centrifugation, the cells were resuspended in DMEM supplemented
with 10% (v/v) FBS, 50 mg/mL streptomycin, and 50 units/mL
penicillin and plated on culture dishes at a density of 5  104 cells/
cm2 with medium replacement every 2 days. To induce cell death,
the chondrocytes from day four cultureswere treatedwith TNF-a in
the presence or absence of CHX. To examine the effect of leptin on
TNF-a-induced chondrocyte death, the cells were pretreated with
leptin for 3 h and were further exposed to TNF-a in the presence or
absence of CHX for the indicated times.
Cell viability assay
Cell viability was determined using the Vi-Cell (Beckman
Coulter, CA) cell counter that performs an automated trypan blue
exclusion assay.
Treatment of TNF-a and pharmacological reagents
To induce cell death, the chondrocytes from day four cultures
were treated with 50 ng/mL TNF-a plus 10 mg/mL CHX. The cells
were pretreated with several pharmacological reagents for 3 h
before TNF-a plus 10 mg/mL CHX treatment.
Assay of mitochondrial membrane potential (MMP)
Disruption of the MMP was measured using a speciﬁc ﬂuores-
cent probe, JC-1, that was added directly to the cell culture medium
(5 mg/mL ﬁnal concentration) and incubated for 15 min at 37C. The
cells were stained with JC-1, and ﬂow cytometry was performed to
measure MMP (an Epics XL; Beckman Coulter). The data were ac-
quired and analyzed using EXPO32 ADC XL 4 color software.
Flow cytometric analysis of Annexin V-FITC binding for apoptosis
Apoptosis was determined by ﬂow cytometry with the Annexin
V-FITC apoptosis detection kit according to the manufacturer's in-
struction. The cells (1  106) were washed twice with ice-cold
phosphate buffered saline (PBS), resuspended in 500 ml of
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FITC and 10 ml PI. The cells were incubated for 10 min at room
temperature in the dark. After double staining, the cells were
analyzed using Epics XL.
PI uptake and staining
The treated or non-treated cells were harvested, and resus-
pended in 0.5 mL of PBS, and stained by incubation with 10 mg/mL
PI and 4 mg/mL Hoechst 33342 for 15 min at 37C. The stained cells
were analyzed using ﬂuorescein activated cell sorter and ﬂuores-
cence microscopy (Zeiss, G}oettingen, Germany).
Nuclear morphology study
The cell suspension was cytospinned onto a clean fat-free glass
slide using a cytocentrifuge. The cytocentrifuged samples were
ﬁxed for 10 min in 4% paraformaldehyde and stained in 4 mg/mL
Hoechst 33342 for 30 min at 37C. The total cell number, at least
300 cells from each experiment, was counted under differential
interference contrast optics and the cells showing condensed or
fragmented nuclei upon Hoechst staining were calculated using
epiﬂuorescence optics by a blind observer.
Quantiﬁcation of DNA hypoploidy and cell cycle phase analysis by
ﬂow cytometry
Ice-cold 95% ethanol with 0.5% Tween 20was added into the cell
suspension to ﬁnal solution of 70% ethanol. The ﬁxed cells were
pelleted andwashedwith PBS containing 1% bovine serum albumin
(BSA). The cells were resuspended in 1 mL of PBS containing
11 Kunitz U/mL RNase, incubated at 4C for 30 min, washed once
with BSA-PBS, and resuspended in PI solution (50 mg/mL). After the
cells had been incubated at 4C for 30 min in the dark and washed
with PBS, the DNA content was measured using an Epics XL
(Beckman Coulter, Fl, USA) and the data were analyzed using the
Multicycle software, which provides a simultaneous estimation of
cell cycle parameters and apoptosis.
Western blot analysis
The cells (2  106) were washed twice with ice-cold PBS,
resuspended in 200 ml of ice-cold solubilizing buffer [300 mMNaCl,
50 mM TriseCl (pH 7.6), 0.5% Triton X-100, 2 mM phenyl-
methanesulfonylﬂuoride, 2 ml/mL aprotinin and 2 ml/mL leupeptin]
and incubated at 4C for 30 min. The lysates were centrifuged at
14,000 rpm for 20 min at 4C. Protein concentrations of the cell
lysates were determined using a Bradford protein assay reagent
(Bio-Rad, Richmond, CA) and 40 mg of proteins were loaded onto
7.5e15% SDS/PAGE. The gels were transferred to a nitrocellulose
membrane (Amersham Pharmacia Biotech, Piscataway, NJ) and
reacted with the indicated antibodies. Immunostaining with anti-
bodies was performed using the SuperSignal West Pico enhanced
chemiluminescence substrate and detected using LAS-3000PLUS
ﬁlm (Fuji Photo Film Company, Kanagawa, Japan).
Co-immunoprecipitation
The cells were collected and lysed in 1 mL of IP lysis buffer
(300 mM NaCl, 500 mM TriseCl (pH7.6), 0.5% Triton X-100, prote-
ase inhibitors, 10 mM Na4P2O7, 1 mM Na3VO4, 25 mM NaF, 1 mM b-
glycerophosphate). Protein concentrations of the cell lysates were
determined using a Bradford protein assay reagent and 500 mg of
protein were precleared and then incubated with anti-
phosphorylated serine antibody in extraction buffer at 4Covernight. The immune-complexes were precipitated using protein
A/G-agarose beads for 2 h, and washed ﬁve times with extraction
buffer prior to boiling in SDS sample buffer. The immunoprecipi-
tated proteins were separated on SDS-PAGE, and western blot
analysis was performed as described above.
Immunoﬂuorescence staining and confocal microscopy
The cells were incubated with anti-cytochrome c antibody for
1 h, washed 3 times for 5 min each, and then incubated with FITC-
conjugated secondary antibody for 1 h at room temperature.
Fluorescent images were observed and analyzed using a Zeiss LSM
700 laser-scanning confocal microscope (G}oettingen, Germany).
Statistical analysis
The six independent experiments were carried out in triplicate.
All data were displayed as means ± 95% conﬁdence interval (CI).
Normality test was checked ShapiroeWilk test and homogeneity of
variances was veriﬁed using Levene's test before statistical analysis.
One-way analysis of variance (ANOVA) followed by Scheffe's post
hoc test was used for the analysis of chondrocytes viability differ-
ences within each treated conditions (according to concentration,
times or treats). Also a linear contrast analysis was used for the
linear trend of between the means of viability based on each
treated concentrations and times group. In case of violation of the
assumption which normality and homogeneity of variance, Krus-
kaleWallis test followed by the ManneWhitney U test was per-
formed to analyze of viability differences within groups. Resulting
tow-tailed P-values <0.05 was regarded as statistically signiﬁcant
difference. SPSS version 21.0 (IBM Corp, Armonk, NY, USA) software
was used for statistical analyses.
Results
Leptin suppresses TNF-a induced chondrocyte death
Previous in vitro studies using chondrocytes showed that TNF-a,
when added alone to the chondrocyte culture medium, did not
induce a signiﬁcant effect on chondrocyte viability; however,
chondrocytes can be sensitized by the co-addition of CHX, an in-
hibitor of translation9. The present study also demonstrated that
TNF-a at a concentration range of 5e100 ng/mL markedly reduced
viability when administered with CHX, but had no signiﬁcant effect
at TNF-a concentrations of 0e100 ng/mL or CHX at 0e15 mg/mL
alone [Fig. 1(A)]. Because the viability of rat chondrocytes treated
for 24 h with 50 ng/mL TNF-a in combination with 10 mg/mL CHX
was approximately 50%, we selected this single combination
treatment for further exploration on the modulation of chon-
drocyte death by leptin [Fig. 1(B)]. Importantly, a range of leptin of
0.5e100 ng/mL markedly suppressed the death of chondrocytes
treated with 50 ng/mL TNF-a in conjunction with 10 mg/mL CHX
[Fig. 1(C)]. To explore the mechanism by which leptin suppresses
TNF-a-induced chondrocyte death, we selected a single dose of
1 ng/mL leptin. Interference light microscopy demonstrated that
leptin almost completely blocked the TNF-a-induced morpholog-
ical changes, supporting the observation that leptin suppresses
TNF-a induced chondrocyte death [Fig. 1(D)].
Apoptosis partially contributes to TNF-a induced chondrocyte death
To examine the cell death mode induced upon TNF-a treatment
in combination with CHX, we carried out several apoptosis ana-
lyses. TNF-a in combination with CHX reduced MMP and induced
the release of cytochrome c from the mitochondria into cytosol
Fig. 1. Leptin suppresses TNF-a-induced chondrocytes death. (A) Cellular viability. TNF-a at 5e100 ng/mL signiﬁcantly reduced viability when administered with CHX. (B) Cellular
viability. Treatment of 50 ng/mL TNF-a with 10 mg/mL CHX for 24 h decreased chondrocyte viability in a time-dependent manner. (C) Cellular viability. Leptin at 0.5e100 ng/mL
signiﬁcantly suppressed the death of chondrocytes treated 50 ng/mL TNF-a in conjunction with 10 mg/mL CHX. (D) Cell morphologies determined using interference light mi-
croscopy. TNF-a increased the morphological appearance of dying cells and leptin almost completely blocked the TNF-a-induced morphological changes. Each experiment, six total,
was conducted with three animals each. In each experiment, the cells from three animals were pooled and analyzed three times. Values are means ± 95% CI.
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apoptotic cells [Fig. 2(B)]; however, the population of subdiploid
apoptotic cells did not account for the amount of dying cells
detected via the viability assay. Although we observed a small
percentage of cells with nuclear condensation, most of the chon-
drocytes treated with TNF-a did not show nuclear condensation
[Fig. 2(C)]. Flow cytometry analysis demonstrated that TNF-a
resulted in an increased accumulation of Annexin V-positive/PI-
positive cells; however, the population of Annexin V-positive cells
was much lower than the amount of dying cells determined via the
viability assay [Fig. 2(D)]. These data suggest that apoptosis only
partially contributes to TNF-a induced chondrocyte death. We next
examined whether zVAD-fmk suppresses TNF-a induced chon-
drocyte death. Noticeably, zVAD-fmk did not suppress TNF-a
induced cell death. Rather, zVAD-fmk augmented TNF-a induced
cell death [Fig. 2(E)].Necroptosis primarily contributes to TNF-a induced chondrocyte
death
Because the augmentation of cell death by zVAD-fmk suggests
that TNF-a induced cell death may be mediated via necroptosis, we
performed several necroptosis analyses. Western blot analysis
showed that TNF-a up-regulated phosphor-cIAP1 and -cIPA2 and
down-regulated XIAP [Fig. 3(A)]. Western blot analysis also showed
that TNF-a up-regulated phosphor-RIP3 and down-regulated RIP1
protein expression levels. Co-immunoprecipitation assays showed
that TNF-a up-regulated phosphorylated RIP3 [Fig. 3(B)]. Viability
assays showed that the pretreatment of zVAD-fmk at 50e100 mM
markedly augmented TNF-a induced chondrocyte death [Fig. 3(C)].
zVAD-fmk inhibited the activation of the effector caspases, caspase-
3 and -7. Importantly, zVAD-fmk augmented the TNF-a-induced
up-regulation of phosphorylated RIP3 and cIAP1 [Fig. 3(D)].
Fig. 2. Apoptosis partially contributes to TNF-a induced chondrocyte death. Rat chondrocytes were pretreated with or without 50 mM zVAD-fmk 3 h before the co-treatment with
50 ng/mL TNF-a with 10 mg/mL CHX. The cells were incubated for an additional 24 h. Ctrl ¼ control (untreated). (A) Representative ﬂow cytometry. TNF-a reduced MMP (Upper
panel). Representative confocal microscopy images. TNF-a induced the release of cytochrome c from rat chondrocyte mitochondria (Lower panel). (B) Representative histograms
showing cell cycle progression and the percentage of subdiploid apoptotic cells (Apo, the percentage of the population undergoing apoptosis). TNF-a slightly increased the
population of subdiploid apoptotic cells. (C) Representative microscopic ﬁgures showing the nuclear morphology revealed by Hoechst 33342. Quantiﬁcation of cells with condensed
nucleus was indicated below the pictures. A few of the cells showed nuclear condensation after treatment with TNF-a. TNF-a slightly increased the population of cells with
condensed nucleus. (D) Representative ﬂow cytometry data. Flow cytometry using Annexin V-FITC/PI double staining demonstrated that TNF-a slightly increased the population of
cells undergoing apoptosis. (E) Cellular viability. Pretreatment of zVAD-fmk signiﬁcantly augmented the reduction in viability of rat chondrocytes treated with TNF-a. Each
experiment, six total, was conducted with three animals each. In each experiment, the cells from three animals were pooled and analyzed three times. Values are means ± 95% CI.
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of viability [Fig. 3(E)]. Necrostatin1 markedly reduced PI uptake in
TNF-a-treated chondrocytes while zVAD-fmk augmented PI uptake
[Fig. 3(F)]. These results suggest that TNF-a induces chondrocyte
death primarily via necroptosis.
Leptin suppressed necroptosis as well as apoptosis in chondrocytes
treated with TNF-a
We next examined by which type of cell death mode leptin in-
hibits cell death in chondrocytes treated with TNF-a. Leptin
inhibited the activation of the effector caspases, caspase-3& -7. Flow
cytometry using Annexin V-FITC/PI double staining demonstrated
that leptin inhibits the increase of Annexin V positive cells. These
data indicate that leptin suppresses the reduction of viability in TNF-
a treated chondrocytes by inhibiting apoptosis [Fig. 4(A)]. Fluores-
cent microscopic images of Hoechst/PI double stained chondrocytes
and their quantiﬁcation showed that leptin markedly decreased the
proportion of PI-positive cells. These data indicate that leptin sup-
presses TNF-a-induced chondrocyte death by inhibiting necroptosis
[Fig. 4(B)]. Taken together, leptin suppressed necroptosis as well as
apoptosis in chondrocytes treated with TNF-a.
Leptin exerts anti-TNF-a activity via JNK
We explored the signaling mechanism by which leptin sup-
presses TNF-a induced chondrocyte death. We ﬁrst examinedERK, JNK and p38 kinases, which are known to be involved in cell
survival and death regulation. To test the effect of pharmacolog-
ical inhibitors against these kinases on TNF-a induced cell death,
we used the JNK inhibitor II (SP600125), ERK inhibitor (PD98059)
and p38 inhibitor (SB202190). Each inhibitor blunted TNF-a
induced cell death [Fig. 5(A)]. Because the JNK inhibitor
SP600125, among the three inhibitors, most prominently sup-
pressed TNF-a induced cell death, we tested whether SP600125
suppressed TNF-a-induced apoptosis and necroptosis. Notably,
SP600125 suppressed the activation of the effector caspases,
caspase-3 and -7 [Fig. 5(B)]. Furthermore, SP600125 decreased
the proportion of PI-positive cells. While SP600125 suppressed
the TNF-a-induced up-regulation of phosphorylated RIP3,
SP600125 reversed the down-regulation of RIP1 [Fig. 5(C)]. These
data indicate that TNF-a-induced chondrocyte apoptosis and
necroptosis is mediated via JNK. Additionally, we examined
whether leptin exerts anti-TNF-a toxicity via JNK. Western blot
assays showed that TNF-a up-regulated the level of phosphory-
lated JNK. Importantly, leptin suppressed the TNF-a-induced up-
regulation of phosphorylated JNK [Fig. 5(D)]. To corroborate that
leptin has the ability to down-regulate the level of phosphory-
lated JNK in chondrocytes, we tested the effect of leptin in
chondrocytes treated with a JNK agonist (ANI). While ANI
prominently up-regulated the level of phosphorylated JNK in
control chondrocytes, leptin prominently down-regulated the
level of phosphorylated JNK [Fig. 5(E)]. These data indicate that
leptin exerts anti-TNF-a activity via JNK.
Fig. 3. Necroptosis primarily contributes to TNF-a induced chondrocyte death. Rat chondrocytes were pretreated with or without 50e100 mM zVAD-fmk or 60 mM necrostatin 13 h
before the co-treatment with 50 ng/mL TNF-a and 10 mg/mL CHX. The cells were incubated for an additional 24 h. Ctrl ¼ control (untreated). (A) Representative western blots
showing that TNF-a up-regulated phosphor-cIAP1 and -cIPA2 and down-regulated XIAP. (B) Representative western blots showing that TNF-a up-regulated phosphor-RIP3 while
TNF-a down-regulated RIP1 protein expression levels (Upper panel). Representative co-immunoprecipitation assays showing that TNF-a up-regulated phosphorylated RIP3 (Lower
panel). (C) Cellular viability. Pretreatment of zVAD-fmk at 50e100 mM signiﬁcantly augmented TNF-a induced chondrocyte death. (D) Representative western blots showing that the
pretreatment of zVAD-fmk completely blocked the activation of the effector caspases, caspase-3 and -7, while the pretreatment of zVAD-fmk markedly augmented the TNF-a-
induced up-regulation of phosphorylated RIP3 and cIAP1. (E) Cellular viability. Necrostatin1 signiﬁcantly suppressed the TNF-a induced reduction of viability. (F) Morphological
signs of apoptosis and necrosis are shown in representative ﬂuorescent microscopic images of Hoechst/PI double stained chondrocytes. The scale bar on the ﬁrst subﬁgure applies to
all of the ﬁgures in the panel. Necrostatin1 markedly reduced PI uptake in TNF-a-treated chondrocytes while zVAD-fmk augmented PI uptake (Upper panel). Necrostatin1
signiﬁcantly reduced PI uptake in TNF-a-treated chondrocytes while zVAD-fmk signiﬁcantly augmented PI uptake. (Lower panel). Each experiment, six total, was conducted with
three animals each. In each experiment, the cells from three animals were pooled and analyzed three times. Values are means ± 95% CI.
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Fig. 4. Leptin suppressed necroptosis as well as apoptosis in chondrocytes treated with TNF-a. The cells were pretreated with 1 ng/mL leptin for 3 h before 50 ng/mL TNF-a plus
10 mg/mL CHX treatment and incubated for an additional 24 h. (A) Representative western blots showing that leptin inhibits TNF-a-induced activation of caspase-3 and -7 and the
production of cleaved PARP (Upper panel). Representative ﬂow cytometry using Annexin V-FITC/PI double staining demonstrates that leptin inhibits the apoptosis induced by TNF-a
(Lower panel). (B) Representative ﬂuorescent microscopic images of Hoechst/PI double stained chondrocytes showing that leptin substantially prevented plasma membrane rupture
in rat chondrocytes treated with TNF-a. The scale bar on the ﬁrst subﬁgure applies to all of the ﬁgures in the panel (Upper panel). Quantiﬁcation indicates that leptin pretreatment
signiﬁcantly decreased PI-positive cells in rat chondrocytes treated with TNF-a (Lower panel). Each experiment, six total, was conducted with three animals each. In each
experiment, the cells from three animals were pooled and analyzed three times. Values are means ± 95% CI.
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Cell death is a fundamental cellular response that plays a crucial
role in shaping our body during development and in regulating
tissue homeostasis by eliminating unwanted cells. Three major
types of cell death have been described based on cell morphology:
apoptosis, autophagic cell death, and necrosis and/or necroptosis.
Previous studies have observed all three of these types of cell death
in chondrocytes7,8,10
Most of the previous studies on chondrocyte death showed that
death is mediated via apoptosis. In addition, most of the previous
studies on the effect of TNF-a on chondrocyte demise reported that
TNF-a induces chondrocyte death via apoptosis. TNF-a stimulates
both pathways for apoptosis induction via receptor-associated
proteins that activate caspases and pathways for the suppression
of apoptosis via the transcriptional factor NF-kB that transactivates
survival genes9,29. Several previous studies demonstrated that TNF-
a also stimulates similar pathways for apoptosis induction in
chondrocytes7,10,30. The present study demonstrated that zVAD-
fmk augmented TNF-a induced cell death although apoptosis at
least in part contributes to TNF-a induced chondrocyte death.
Previous studies showed that the auto- and trans-phosphorylation
of RIP1 and RIP3 and the recruitment of mixed lineage kinasedomain-like (MLKM) initiates necroptosis when capase-8 is
inhibited by zVAD-fmk, RIPK1 and RIPK3 associate and form the
necrotosomes31.
Many cell types that cannot initiate or propagate the apoptotic
signaling cascade die via necroptosis. Necroptosis is typically not
associated with the activation of caspases and is characterized by
cytoplasmic swelling, irreversible plasma membrane damage, and
organelle breakdown32,33. In cells undergoing necroptosis, receptor
interacting protein-1 (RIP1) is phosphorylated, and then interacts
with RIP3 via RIP homotypic interaction motif domains, leading to
necroptosis. Necroptosis is found to be activated when apoptosis
pathways are blocked under certain circumstances; however, nec-
roptosis may be predominant even when the apoptosis pathways
are competent, indicating that necroptosis can be either a backup or
an alternative cell death mode34. TNF-a-induced necroptosis has
been extensively studied35 and a few previous studies demon-
strated that chondrocyte death can be mediated via necroptosis30.
Autophagy is a degradative lysosomal pathway that is charac-
terized by the accumulation of cytoplasmic material in autophagic
vacuoles for bulk degradation by lysosomal enzymes. Although
autophagy plays a pivotal role in cell survival, increased autophagic
activity is often associated with cell death. A previous study
elucidated that TNF-a induces chondrocyte death via autophagic
Fig. 5. Leptin exerts anti-TNF-a cytotoxicity via JNK. The cells were pretreated with 10 mM JNK inhibitor (JNKI), 10 mM ERK inhibitor (ERKI), 10 mM p38 inhibitor (p38I) or 10e30 mg/
mL ANI with or without 1 ng/mL leptin, for 3 h before 50 ng/mL TNF-a plus 10 mg/mL CHX treatment and incubation for an additional 24 h. (A) JNK inhibitor (JNKI), ERK inhibitor
(ERKI), or p38 inhibitor (p38I) signiﬁcantly prevented TNF-a induced reduction of cell viability. (B) Representative western blots showing that JNKI inhibits the activation of the
effector caspases, caspase-3 and -7. (C) The quantiﬁcation indicates that JNKI pretreatment signiﬁcantly decreased PI-positive cells in rat chondrocytes treated with TNF-a. (Upper
panel). Representative western blots showing that JNKI inhibited the TNF-a-induced up-regulation of phosphorylated RIP3 and reversed the TNF-a-induced down-regulation of
RIP1 (Lower panel). (D) Representative western blots showing that leptin inhibits the TNF-a-induced up-regulation of phosphorylated JNK in rat articular chondrocytes (Upper
panel). Leptin or CHX at doses used has no effect on the level of phosphorylated JNK (Lower panel). (E) Representative western blots showing that leptin efﬁciently blocks JNK
agonist (ANI)-induced up-regulation of phosphorylated JNK. Each experiment, six total, was conducted with three animals each. In each experiment, the cells from three animals
were pooled and analyzed three times. Values are means ± 95% CI.
S.W. Lee et al. / Osteoarthritis and Cartilage 23 (2015) 2269e22782276cell death10. The present study demonstrated that TNF-a induces
necroptosis as well as apoptosis in rat articular chondrocytes.
Leptin, the protein product of the ob gene that is the murine
homologue of the human LEP gene14, exerts its biological actions
through the activation of its OB-Rb long-form receptor isoform that
is encoded via the gene diabetes (db) and belongs to the class one
cytokine receptor superfamily. This hormone decreases food intake
by increasing anorexigenic factors including cocaine- and
amphetamine-related transcript (CART) and increases energy
consumption by suppressing orexigenic neuropeptides such as
neuropeptide Y (NPY)36. Leptin levels are mostly dependent on the
amount of body fat, but its synthesis is also regulated by inﬂam-
matory mediators37.
There is evidence of increased leptin levels in patients with
radiographically more severe OA compared with controls and pa-
tients with radiographically less severe OA38. A recent study by
Ding et al. demonstrated a negative association of serum leptin
levels to cartilage volume in 190 randomly selected patients39.
Additionally, leptin mRNA expression in OA cartilage and the levels
of leptin and leptin receptor (Ob-Rb) expression in human OA
cartilage have been found to be related to the severity of cartilagedestruction40. In an in vivomodel, leptin injection into the rat knee
led to an increased synthesis of insulin-like growth factor-1 (IGF-I),
transforming growth factor b (TGF-b) and leptin itself21. Therefore,
leptin plays a catabolic role in cartilage metabolism and may be a
factor involved in the pathological process of OA. The levels of
leptin are increased in the synovial ﬂuid as well as the serum of
patients with OA41. Although some initial ﬁndings have suggested
an anabolic role of this hormone in the cartilage21, most of the
studies reveal a catabolic role of leptin at the cartilage level.
Recently, researchers have demonstrated that leptin is also able to
induce the expression of MMPs involved in OA cartilage damage,
such as MMP-9 and MMP-1342.
During OA, chondrocytes exhibit aberrant behavior including
increased matrix degradation and reduced anabolic processes,
resulting in an imbalance of cartilage homeostasis. The most
prominent feature of OA is cartilage destruction due to an unbal-
anced production of catabolic and anabolic factors by chondrocytes.
Leptin regulates chondrocyte functions and appears to primarily
push the balance towards inﬂammation and destruction. Leptin has
been shown to enhance the production of pro-inﬂammatory factors
and destructive mediators acknowledged in the pathogenesis of
S.W. Lee et al. / Osteoarthritis and Cartilage 23 (2015) 2269e2278 2277OA, such as IL-1b, IL-6, IL-8, vascular cell adhesion molecule-1
(VCAM-1), NO and prostaglandin E2 (PGE2) by articular chon-
drocytes22,43,44, and decrease the proliferation of cultured human
chondrocytes22. Leptin signals via binding to the leptin receptor
(OB-Rb), and the intracellular signaling mechanisms described to
be activated by leptin include JAK-STAT, phospho-inositide 3-kinase
(PI3K), nuclear factor kB (NF-kB) and protein kinase C (PKC) path-
ways as well as mitogen-activated protein kinases (MAPK)
including extracellular signal-regulated kinase (Erk1/2), p38 kinase
and JNK45.
Most of the previous reports indicate that leptin plays a cata-
bolic role in the cartilage, while data obtained from the present
study supports a role for leptin in suppression of TNF-a induced
chondrocyte death. Based on our ﬁndings, we suggest that leptin
present in the articular joint ﬂuid protects articular chondrocytes
against cumulative mechanical load and detrimental stresses
throughout the lifetime, delaying the onset of degenerative
changes in chondrocytes. Our assumption can be supported by the
observation that OA is common in the aged population. We can
further hypothesize that leptin protects articular chondrocytes
against destructive stimuli even in the joint of OA patients.
Although most of the previous studies indicate that leptin is
involved in OA cartilage damage, our ﬁndings suggest that leptin in
the joint of OA patients presumably slows or halts OA progression.
A previous study showing that the ratio of synovial ﬂuid to plasma
leptin was signiﬁcantly lower in the advanced OA stage compared
with early stages of the disease46 supports our assumption. Previ-
ous studies indicate that leptin regulates inﬂammation. Although
most studies supported the pro-inﬂammatory activity of leptin,
anti-inﬂammatory effects also have been described for leptin ac-
cording to the experimental model investigated. Thus, leptin ap-
pears to play both pro- and anti-inﬂammatory roles47. Several
previous studies demonstrated anti-inﬂammatory effects of leptin
on arthritis. Leptin showed a protective role against
RA destruction48, recombinant leptin relieved the severity of joint
manifestations in Staphylococcus aureus-induced arthritis as well as
the inﬂammatory response49, and leptin appeared to play an
important role in maintaining energy homeostasis in the anti-
inﬂammatory responses during RA remission50. These ﬁndings in
conjunctionwith our ﬁndings suggest that leptin may contribute to
the reduction of joint damage by exerting anti-inﬂammatory
activity.
Taken together, our ﬁndings suggest that leptin suppresses TNF-
a induced chondrocyte death; however, further studies are
required to extend these in vitro data to the in vivo situation.
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